Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Feb 1;13(1):128-131.
doi: 10.21037/hbsn-23-563. Epub 2024 Jan 18.

Advancing towards accurate phenotyping based on metabolic and fibrosis risk in metabolic-dysfunction associated steatotic liver disease: one step closer to personalized care

Sergio Muñoz-Martínez  1   2 , Alba Jiménez-Masip  1   3 , Juan M Pericàs  1   3   4
Affiliations
Editorial

Advancing towards accurate phenotyping based on metabolic and fibrosis risk in metabolic-dysfunction associated steatotic liver disease: one step closer to personalized care

Sergio Muñoz-Martínez et al. Hepatobiliary Surg Nutr. .
No abstract available

Keywords: Metabolic-dysfunction associated steatotic liver disease (MASLD); advanced fibrosis; non-invasive tests (NITs); type 2 diabetes (T2D).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-23-563/coif). S.M.M. reports grant for educational development from Bristol-Myers Squibb, payment honoraria for lectures from Bayer and Asopharma and travel and meeting funding from Bayer, Eisai and MSD. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol 2022;10:284-96. 10.1016/S2213-8587(22)00003-1 - DOI - PubMed
    1. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023;79:1542-56. 10.1016/j.jhep.2023.06.003 - DOI - PubMed
    1. Sanyal AJ, Van Natta ML, Clark J, et al. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. N Engl J Med 2021;385:1559-69. 10.1056/NEJMoa2029349 - DOI - PMC - PubMed
    1. Castera L, Laouenan C, Vallet-Pichard A, et al. High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold. Diabetes Care 2023;46:1354-62. 10.2337/dc22-2048 - DOI - PubMed
    1. Huang DQ, Noureddin N, Ajmera V, et al. Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis. Lancet Gastroenterol Hepatol 2023;8:829-36. 10.1016/S2468-1253(23)00157-7 - DOI - PMC - PubMed